Apogee net loss widens to $85.85 million in Q2 FY26; R&D expenses rise to $67.3 million
Reuters2026/08/10 11:06- Apogee Therapeutics posted a Q2 2026 net loss of $85.85 million, widening from $66.1 million a year earlier.
- R&D expenses rose 20.82% to $67.3 million, while G&A costs climbed 39.38% to $24.34 million, both versus Q2 2025.
- Cash, cash equivalents and marketable securities totaled $1.3 billion at June 30, 2026, up from $621.2 million a year earlier.
- June 2026 deal calls for AbbVie to buy Apogee for $135.11 per share in cash, valuing equity at about $10.9 billion; closing expected Q3 2026.
- Phase 2 APEX Part B met endpoints; 65.9% on mid-dose zumilokibart achieved EASI-75 at Week 16, supporting planned Phase 3 start this year.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Today's Fear & Greed Index rises to 65, indicating the market is in a 'greed' state.
CFTC files motion to dismiss CME's motion regarding perpetual contracts lawsuit
At a sensitive moment of the "bond market storm," the market focuses on today's 30-year Japanese government bond auction.
Japan’s 30-year government bond yield has risen to 4.155%, approaching a historic high. The 30-year bond auction scheduled for Thursday is drawing significant attention. Analysts generally expect a weak result and warn that if the auction goes poorly, it could put reverse pressure on US Treasuries, prompting a repricing of the global fixed income market and potentially becoming a new trigger for rising global borrowing costs.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
